Omega-3 may be an “effective add-on therapeutic” for depression
A new review investigating the effect of long-chain omega-3 supplementation on depressive symptoms concludes the majority of studies observe a significant effect, particularly in those with major depressive disorder.
FAB RESEARCH COMMENT:
Numerous ransomdised controlled clinical trials have shown significant reductions in depressive symptoms from adjunctive treatment with the omega-3 long-chain polyunsaturated fatty acids (LC-PUFA) found in fish and seafood - and particularly EPA - since initial reports more than 20 years ago. (Peet & Horrobin 2002 - A dose-ranging study of EPA treatment in depression)This new review focused on published meta-analyses of clinical trials to date - of which a clear majority (16/22) showed benefits from dietary supplementation with omega-3 - and that the improvements appear to be greatest for:
- patients with clinical level depression, and
- doses of at least 1-2g/day of EPA
For details of this new research, see:
For further information please see:
See also:
06/11/23 - Nutraingredients
--------------------------------
A new umbrella review of meta-analyses investigating the effect of long-chain omega-3 supplementation on depressive symptoms concludes the majority of studies observe a significant effect, particularly in those with major depressive disorder (MDD).
--------------------------------
A new umbrella review of meta-analyses investigating the effect of long-chain omega-3 supplementation on depressive symptoms concludes the majority of studies observe a significant effect, particularly in those with major depressive disorder (MDD).
The review also observed a direct relationship between the polyunsaturated fatty acids (PUFAs) dosage and the effect size on depression, with eicosapentaenoic acid (EPA) demonstrating a greater effect over docosahexaenoic acid (DHA).
Regarding the ‘British Journal of Nutrition’ published findings, the Chinese researchers conclude: “Omega-3 PUFAs supplementation could be considered as an effective therapeutic adjuvant approach in relieving depression symptoms.”
Omegas and the mind
Depression is a highly common condition of the modern world, affecting an array of areas such as sleep quality, energy levels, and appetite. The World Health Organization has previously predicted that it may affect 280 million people globally, with levels ever-increasing following the Covid-19 pandemic.
Research has shown that factors such as nutrition, genetics, environment, and hormones play major roles in the pathogenesis of depression, with alterations noted in the levels of serotonin, dopamine, and gamma -aminobutyric acid (GABA).
Following long-term concerns around the effectiveness and adversities associated with the use of anti-depressants, there has been significant interest in investigating further causes of depression and more natural treatment methods. It is known that long-chain fatty acids (n-3 PUFAs), specifically EPA and DHA, have significant benefits such as anti-inflammatory and subsequent neuro-inflammatory inhibitory activities.
Whilst previous meta-analyses have investigated the association between omega-3 FAs and depression, there has been a lack of a really conclusive outcome. Thus, the researchers conducted an umbrella review of such meta-analyses to further establish a definite conclusion.
Review findings
The researchers searched the databases of PubMed, Scopus, Embase, Web of Science, and Cochrane Central Library to collate meta-analyses investigating the effects of n-3 PUFAs on depressive symptoms. Twenty-two meta-analyses were included following the search.
The findings revealed a significant improvement effect on depressive symptoms in the majority of included studies, with 16 effect sizes displaying this association.
Supplement dosages displaying significant effects ranged from 0.09-3.4g of DHA and 0.009-6.2 g of EPA.
The association was observed to be more pronounced in those with major depressive disorder (MDD), when compared to those with mild depressive symptoms. Furthermore, there was a direct relationship between the dosages of omega-3 PUFAs and the effect size on depression, with EPA demonstrating a greater effect over DHA.
Explained
Based on the findings, the report concluded that omega-3 supplements may present an efficacious add-on therapeutic approach in relieving depression symptoms.
Explaining the mechanism of action, the researchers said:
“Omega-3 PUFAs have been proven to influence the activity and structure of brain through affecting adult neurogenesis and synaptogenesis by increasing the signalling factors involved in neurogenesis, such as brain-derived neurotrophic factor (BDNF), cAMP response element-binding protein (CREB), or calcium/calmodulin-dependent protein kinase II (CaMKII).
“Omega-3 PUFAs have been proven to influence the activity and structure of brain through affecting adult neurogenesis and synaptogenesis by increasing the signalling factors involved in neurogenesis, such as brain-derived neurotrophic factor (BDNF), cAMP response element-binding protein (CREB), or calcium/calmodulin-dependent protein kinase II (CaMKII).
“In one pathway, omega-3 PUFAs might increase the expression of dopamine receptor; whereby increase dopamine activity as a neurotransmiter in restoring the mood (81).
"As well, omega-3 PUFAs were effective in balancing the low level of BDNF (brain-derived neurotrophic factor) among depressed patients. BDNF could boost the action of antidepressant agents,” they added.
"As well, omega-3 PUFAs were effective in balancing the low level of BDNF (brain-derived neurotrophic factor) among depressed patients. BDNF could boost the action of antidepressant agents,” they added.
Yet, the report emphasised the need for further research to account for significant between-study heterogeneity and a lack of insight into factors such as dose, duration of supplementation and gender.
Food and Behaviour Research is a registered charity (No SC034604) and a company limited by guarantee (Co No SC 253448)
Newsletter Signup
Useful Links
Contact Us
FAB Research
23 Carlton Road
Oxford
OX2 7SA
Important Notice
Medical opinion and guidance should always be sought for any symptoms that might possibly reflect a known or suspected disease, disorder or medical condition. Information provided on this website (or by FAB Research via any other means) does not in any way constitute advice on the treatment of any medical condition formally diagnosed or otherwise.
Site by Redstone Websites. Easy to Use Web Content Management. 2025 © All Rights Reserved.